Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY)

AIDS

Volumn 21, Issue 10, 2007, Pages 1323-1331

  Piroth, Lionel ^a   Sène, Damien ^b,c   Pol, Stanislas ^d   Goderel, Isabelle ^e   Lacombe, Karine ^f   Martha, Benoit ^a   Rey, David ^g   Loustau Ratti, Véronique ^h   Bergmann, Jean François ⁱ   Pialoux, Gilles ^j   Gervais, Anne ^k   Lascoux Combe, Caroline ^l   Carrat, Fabrice ^e   Cacoub, Patrice ^b,c  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d CHU Cochin ^*  (France)

^e INSERM   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h LIMOGES UNIVERSITY HOSPITAL   (France)

ⁱ HÔPITAL LARIBOISIÈRE   (France)

^j HÔPITAL TENON   (France)

^k BICHAT HOSPITAL   (France)

^l SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

Co infection; Evolution; Hepatitis B virus; HIV; Treatment

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; EMTRICITABINE; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON; TENOFOVIR;

ADULT; ARTICLE; CHRONIC HEPATITIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIAGNOSTIC VALUE; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; SEROCONVERSION; STANDARDIZATION; SUPERINFECTION; TREATMENT OUTCOME; VIRUS DIAGNOSIS; WILD TYPE;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; FRANCE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; LIVER; MALE; RETROSPECTIVE STUDIES;

EID: 34250003166     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32810c8bcf     Document Type: Article

References (33)

1. Sene D, Pol S, Piroth L, Goujard C, Dellamonica P, Moussali J, et al. Hepatitis B virus-human immunodeficiency virus co-infection in France: a cross-sectional multicentre study. Epidemiol Infect 2007; 135:409-416.
2. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006; 44:S65-S70.
3. Thio C, Seaberg E, Skolasky R, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926.
4. Bonacini M, Louie S, Bzowej N, Wohl A. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004; 18:2039-2046.
5. Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42:799-805.
6. Hatzakis A, Magiorkinis E, Haida C. HBV virological assessment. J Hepatol 2006; 44:S71-S76.
7. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42:615-624.
8. McMahon BJ. Selecting appropriate management strategies for chronic hepatitis B: who to treat. Am J Gastroenterol 2006; 101(suppl 1):S7-S12.
9. Piroth L, Binquet C, Vergne M, Minello A, Livry C, Bour J, et al. The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol 2002; 36:681-686.
10. Hadler SC, Judson FN, O'Malley PM, Altman NL, Penley K, Buchbinder S, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991; 163:454-459.
11. Colin J, Cazals-Hatem D, Loriot M, Martinot-Peignoux M, Nga Pham B, Auperin A, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:1306-1310.
12. Lok A, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34:1225-1241.
13. Ribeiro R, Lo A, Perelson A. Dynamics of hepatitis B virus infection. Microbes Infect 2002; 4:829-835.
14. Niederau C, Heintges T, Lange S. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334:1422-1427.
15. Zoulim F. Assessment of treatment efficacy in HBV infection and disease. J Hepatol 2006; 44 (suppl 1):S95-S99.
16. Benhamou Y, Thibault V, Vig P, Calvez V, Marcelin AG, Fievet MH, et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006; 44:1-3.
17. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292-297.
18. Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, et al. Resistance to adefovir dipivoxil (ADV) in lamivudine- resistant chronic hepatitis B patients treated with ADV. Gut 2006; 55:1488-1495.
19. Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43:1385-1391.
20. Gelinck LB, Claas EC, Kroon FP. The risk of adefovir monotherapy in human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infected patients. J Hepatol 2005; 43:360-361; author reply 361.
21. Sheldon JA, Corral A, Rodes B, Mauss S, Rockstroh J, Berger F, et al. Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS 2005; 19:2036-2038.
22. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10:761-763.
23. Zylberberg H, Jiang J, Pialoux G, Driss F, Carnot F, Dubois F, et al. Alpha-interferon for chronic active hepatitis B in human immunodeficiency virus-infected patients. Gastroenterol Clin Biol 1996; 20:968-971.
24. Di Martino V, Thevenot T, Colin J, Boyer N, Martinot M, Degos F, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002; 123:1812-1822.
25. Wolters LM, Niesters HG, Hansen BE, van der Ende ME, Kroon FP, Richter C, et al. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol 2002; 24:173-181.
26. Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006; 44:1110-1116.
27. Stephan C, Berger A, Carlebach A, Lutz T, Bickel M, Klauke S, et al. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J Antimicrob Chemother 2005; 56:1087-1093.
28. Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006; 43:548-555.
29. Nunez M, Soriano V. Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect Dis 2005; 5:374-382.
30. Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189:1185-1192.
31. Bani-Sadr F, Palmer P, Scieux C, Molina JM. Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus. Clin Infect Dis 2004; 39:1062-1064.
32. Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, et al. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol 2005; 100:2463-2471.
33. Serfaty L, Thabut D, Zoulim F. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 2001; 34:534-537.